Chugai Seiyaku Kabushiki Kaisha

Tomoyuki Igawa

Hirotake Shiraiwa

Shojiro Kadono

Hidetomo Kitamura

Hitoshi Katada

Naoka Hironiwa

Yuji Hori

Shun Shimizu

Mika Sakurai

Taro Miyazaki

Hiroki Kawauchi

Shu Feng

Kanako Tatsumi

Masami Hasegawa

Masaki Kamimura

Yoshinori Narita

Taichi Kuramochi

Akira Hayasaka

Shu Wen Samantha Ho

Yang Sun

Takeaki Kawai

Takayuki Kamikawa

Nasa Savory

Futa Mimoto

Maiko Hoshino

Wenjie Tu

Yuki Noguchi

Yutaka Matsuda

An antigen-binding molecule capable of binding to multiple different antigens (e.g., CD3 on T cells, and CD137 on T cells, NK cells, DC cells, and/or the like), but does not nonspecifically crosslink two or more immune cells such as T cells is provided. Such multispecific antigen-binding molecule is capable of modulating and/or activating an immune response while circumventing the cross-linking between different cells (e.g., different T cells) resulting from the binding of a conventional multispecific antigen-binding molecule to antigens expressed on the different cells, which is considered to be responsible for adverse reactions when the multispecific antigen-binding molecule is used as a drug.

Antigen-binding molecule comprising altered antibody variable region

An objective of the present disclosure is to provide anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, and methods of using the same. Anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, are provided by discovering and producing CD137 antigen-binding molecules whose binding activity to CD137 depends on various substances (for example, small molecule compounds) in target tissues. Methods of using the same, pharmaceutical formulations, and such are also provided. The present disclosure also provides an antigen-binding molecule whose binding activity to an antigen varies depending on a small molecule compound, a preparation method thereof, and uses thereof.

Anti-CD137 antigen-binding molecule and utilization thereof

The present invention provides a polypeptide comprising an antigen binding domain which binds to an antigen present in cartilage tissue, and also provides use of the polypeptide. The polypeptide of the invention is useful for penetrating and/or retaining a desired substance in the cartilage tissue for a long period. The present invention further relates to a polypeptide comprising (i) an antigen binding domain which binds to a molecule in a cartilage tissue, and (ii) a carrying moiety having an inhibiting domain that inhibits the antigen binding activity of the antigen binding domain, and having a longer half-life than that of the antigen binding domain existing alone, and a pharmaceutical composition comprising the polypeptide. The present invention further relates to methods for producing and screening for the polypeptide.

Polypeptide comprising aggrecan binding domain and carrying moiety

Growing community of inventors

Singapore, Singapore

Tomoyuki Igawa